Signal Transduction Cascades Controlling Osteoblast Differentiation

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition

Volumn , Issue , 2013, Pages 15-24

  de Gorter, David J J ^a   ten Dijke, Peter ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Mesenchymal stem cells (MSCs); Osteoblast differentiation; Signal transduction cascades

Indexed keywords

EID: 84964040784     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118453926.ch2     Document Type: Chapter

References (81)

1. Caplan AI, Bruder SP. 2001. Mesenchymal stem cells: Building blocks for molecular medicine in the 21st century. Trends MolMed 7 (6): 259-64.
2. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, et al. 2002. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418 (6893): 41-9.
3. Stein GS, Lian JB. 1993. Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. EndocrRev 14 (4): 424-42.
4. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, et al. 1997. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89 (5): 765-71.
5. Mundlos S. 1999. Cleidocranial dysplasia: Clinical and molecular genetics. J Med Genet 36 (3): 177-82.
6. Harada H, Tagashira S, Fujiwara M, Ogawa S, Katsumata T, Yamaguchi A, et al. 1999. Cbfa1 isoforms exert functional differences in osteoblast differentiation. J Biol Chem 274 (11): 6972-8.
7. Kern B, Shen J, Starbuck M, Karsenty G. 2001. Cbfa1 contributes to the osteoblast-specific expression of type I collagen genes. J Biol Chem 276 (10): 7101-7.
8. Nishio Y, Dong Y, Paris M, O ' Keefe RJ, Schwarz EM, Drissi H. 2006. Runx2-mediated regulation of the zinc finger Osterix/Sp7 gene. Gene 372: 62-70.
9. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, et al. 2002. The novel zinc fingercontaining transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108 (1): 17-29.
10. Koga T, Matsui Y, Asagiri M, Kodama T, de Crombrugghe B, Nakashima K, et al. 2005. NFAT and Osterix cooperatively regulate bone formation. Nat Med 11 (8): 880-5.
11. Urist MR. 1965. Bone: formation by autoinduction. Science 150 (698): 893-9.
12. Chen D, Zhao M, Mundy GR. 2004. Bone morphogenetic proteins. Growth Factors 22 (4): 233-41.
13. Gazzerro E, Canalis E. 2006. Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord 7 (1-2): 51-65.
14. Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, et al. 2006. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38 (5): 525-7.
15. van Dinther M, Visser N, de Gorter DJJ, Doorn J, Goumans MJ, de Boer J, et al. 2010. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J Bone Miner Res 25 (6): 1208-15.
16. Gautschi OP, Frey SP, Zellweger R. 2007. Bone morphogenetic proteins in clinical applications. ANZ J Surg 77 (8): 626-31.
17. Feng XH, Derynck R. 2005. Specificity and versatility in tgf-β signaling through Smads. Annu Rev Cell Dev Biol 21: 659-93.
18. Massague J, Seoane J, Wotton D. 2005. Smad transcription factors. Genes Dev 19 (23): 2783-810.
19. Lee KS, Kim HJ, Li QL, Chi XZ, Ueta C, Komori T, et al. 2000. Runx2 is a common target of transforming growth factor β 1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 20 (23): 8783-92.
20. Javed A, Bae JS, Afzal F, Gutierrez S, Pratap J, Zaidi SK, et al. 2008. Structural coupling of Smad and Runx2 for execution of the BMP2 osteogenic signal. J Biol Chem 283 (13): 8412-22.
21. Zhang YW, Yasui N, Ito K, Huang G, Fujii M, Hanai J, et al. 2000. A RUNX2/PEBP2 α A/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. Proc Natl Acad Sci U S A 97 (19): 10549-54.
22. Pereira RC, Rydziel S, Canalis E. 2000. Bone morphogenetic protein-4 regulates its own expression in cultured osteoblasts. J Cell Physiol 182 (2): 239-46.
23. Korchynskyi O, ten Dijke P. 2002. Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem 277 (7): 4883-91.
24. Ogata T, Wozney JM, Benezra R, Noda M. 1993. Bone morphogenetic protein 2 transiently enhances expression of a gene, Id (inhibitor of differentiation), encoding a helix-loop-helix molecule in osteoblast-like cells. Proc Natl Acad Sci U S A 90 (19): 9219-22.
25. Maeda Y, Tsuji K, Nifuji A, Noda M. 2004. Inhibitory helix-loop-helix transcription factors Id1/Id3 promote bone formation in vivo. J Cell Biochem 93 (2): 337-44.
26. Celil AB, Campbell PG. 2005. BMP-2 and insulin-like growth factor-I mediate Osterix (Osx) expression in human mesenchymal stem cells via the MAPK and protein kinase D signaling pathways. J Biol Chem 280 (36): 31353-9.
27. Celil AB, Hollinger JO, Campbell PG. 2005. Osx transcriptional regulation is mediated by additional pathways to BMP2/Smad signaling. J Cell Biochem 95 (3): 518-28.
28. Janssens K, ten Dijke P, Janssens S, Van Hul W. 2005. Transforming growth factor-β 1 to the bone. Endocr Rev 26 (6): 743-74.
29. Alliston T, Choy L, Ducy P, Karsenty G, Derynck R. 2001. TGF-β-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J 20 (9): 2254-72.
30. Maeda S, Hayashi M, Komiya S, Imamura T, Miyazono K. 2004. Endogenous TGF-β signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO J 23 (3): 552-63.
31. Sowa H, Kaji H, Yamaguchi T, Sugimoto T, Chihara K. 2002. Smad3 promotes alkaline phosphatase activity and mineralization of osteoblastic MC3T3-E1 cells. J Bone Miner Res 17 (7): 1190-9.
32. Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo WH, et al. 1999. Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline C α promoter. J Biol Chem 274 (44): 31577-82.
33. Clevers H. 2006. Wnt/ β-catenin signaling in development and disease. Cell 127 (3): 469-80.
34. Day TF, Guo X, Garrett-Beal L, Yang Y. 2005. Wnt/ β-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 8 (5): 739-50.
35. Hill TP, Spater D, Taketo MM, Birchmeier W, Hartmann C. 2005. Canonical Wnt/ β-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 8 (5): 727-38.
36. Hu H, Hilton MJ, Tu X, Yu K, Ornitz DM, Long F. 2005. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 132 (1): 49-60.
37. Kramer I, Halleux C, Keller H, Pegurri M, Gooi JH, Weber PB, et al. 2010. Osteocyte Wnt/ β-catenin signaling is required for normal bone homeostasis. Mol Cell Biol 30 (12): 3071-85.
38. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, et al. 2002. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346 (20): 1513-21.
39. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, et al. 2002. A mutation in the LDL receptorrelated protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70 (1): 11-9.
40. Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Benichou O, Scopelliti D, et al. 2003. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 72 (3): 763-71.
41. ten Dijke P, Krause C, de Gorter DJJ, Lowik CW, van Bezooijen RL. 2008. Osteocyte-derived sclerostin inhibits bone formation: Its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am 90 (Suppl 1): 31-5.
42. St Jacques B, Hammerschmidt M, McMahon AP. 1999. Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev 13 (16): 2072-86.
43. Long F, Chung UI, Ohba S, McMahon J, Kronenberg HM, McMahon AP. 2004. Ihh signaling is directly required for the osteoblast lineage in the endochondral skeleton. Development 131 (6): 1309-18.
44. Hooper JE, Scott MP. 2005. Communicating with Hedgehogs. Nat Rev Mol Cell Biol 6 (4): 306-17.
45. Hui CC, Joyner AL. 1993. A mouse model of greig cephalopolysyndactyly syndrome: The extra-toesJ mutation contains an intragenic deletion of the Gli3 gene. Nat Genet 3 (3): 241-6.
46. Litingtung Y, Dahn RD, Li Y, Fallon JF, Chiang C. 2002. Shh and Gli3 are dispensable for limb skeleton formation but regulate digit number and identity. Nature 418 (6901): 979-83.
47. Shimoyama A, Wada M, Ikeda F, Hata K, Matsubara T, Nifuji A, et al. 2007. Ihh/Gli2 signaling promotes osteoblast differentiation by regulating Runx2 expression and function. Mol Biol Cell 18 (7): 2411-8.
48. Rubin MR, Bilezikian JP. 2003. New anabolic therapies in osteoporosis. Endocrinol Metab Clin North Am 32 (1): 285-307.
49. Karaplis AC, Luz A, Glowacki J, Bronson RT, Tybulewicz VL, Kronenberg HM, et al. 1994. Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes Dev 8 (3): 277-89.
50. Miao D, He B, Karaplis AC, Goltzman D. 2002. Parathyroid hormone is essential for normal fetal bone formation. J Clin Invest 109 (9): 1173-82.
51. Weir EC, Philbrick WM, Amling M, Neff LA, Baron R, Broadus AE. 1996. Targeted overexpression of parathyroid hormone-related peptide in chondrocytes causes chondrodysplasia and delayed endochondral bone formation. Proc Natl Acad Sci U S A 93 (19): 10240-5.
52. Lanske B, Karaplis AC, Lee K, Luz A, Vortkamp A, Pirro A, et al. 1996. PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science 273 (5275): 663-6.
53. Zhang P, Jobert AS, Couvineau A, Silve C. 1998. A homozygous inactivating mutation in the parathyroid hormone/parathyroid hormone-related peptide receptor causing Blomstrand chondrodysplasia. J Clin Endocrinol Metab 83 (9): 3365-8.
54. Krishnan V, Moore TL, Ma YL, Helvering LM, Frolik CA, Valasek KM, et al. 2003. Parathyroid hormone bone anabolic action requires Cbfa1/Runx2-dependent signaling. Mol Endocrinol 17 (3): 423-35.
55. van der Horst G, Farih-Sips H, Lowik CW, Karperien M. 2005. Multiple mechanisms are involved in inhibition of osteoblast differentiation by PTHrP and PTH in KS483 Cells. J Bone Miner Res 20 (12): 2233-44.
56. Canalis E. 2009. Growth factor control of bone mass. J Cell Biochem 108 (4): 769-77.
57. Bikle D, Majumdar S, Laib A, Powell-Braxton L, Rosen C, Beamer W, et al. 2001. The skeletal structure of insulin-like growth factor I-deficient mice. J Bone Miner Res 16 (12): 2320-9.
58. Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, Jacobs J, et al. 2003. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 17 (11): 1352-65.
59. Fujita T, Azuma Y, Fukuyama R, Hattori Y, Yoshida C, Koida M, et al. 2004. Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J Cell Biol 166 (1): 85-95.
60. Yang S, Xu H, Yu S, Cao H, Fan J, Ge C, et al. 2011. Foxo1 mediates insulin-like growth factor 1 (IGF1)/ insulin regulation of osteocalcin expression by antagonizing Runx2 in osteoblasts. J Biol Chem 286 (21): 19149-58.
61. Matsuguchi T, Chiba N, Bandow K, Kakimoto K, Masuda A, Ohnishi T. 2009. JNK activity is essential for Atf4 expression and late-stage osteoblast differentiation. J Bone Miner Res 24 (3): 398-410.
62. Ornitz DM. 2005. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev 16 (2): 205-13.
63. Eswarakumar VP, Monsonego-Ornan E, Pines M, Antonopoulou I, Morriss-Kay GM, Lonai P. 2002. The IIIc alternative of Fgfr2 is a positive regulator of bone formation. Development 129 (16): 3783-93.
64. Yu K, Xu J, Liu Z, Sosic D, Shao J, Olson EN, et al. 2003. Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. Development 130 (13): 3063-74.
65. Kim HJ, Kim JH, Bae SC, Choi JY, Ryoo HM. 2003. The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2. J Biol Chem 278 (1): 319-26.
66. Ehebauer M, Hayward P, Martinez-Arias A. 2006. Notch signaling pathway. Sci STKE 2006 (364): cm7.
67. Deregowski V, Gazzerro E, Priest L, Rydziel S, Canalis E. 2006. Notch 1 overexpression inhibits osteoblastogenesis by suppressing Wnt/ β-catenin but not bone morphogenetic protein signaling. J Biol Chem 281 (10): 6203-10.
68. Zamurovic N, Cappellen D, Rohner D, Susa M. 2004. Coordinated activation of notch, Wnt, and transforming growth factor-β signaling pathways in bone morphogenic protein 2-induced osteogenesis. Notch target gene Hey1 inhibits mineralization and Runx2 transcriptional activity. J Biol Chem 279 (36): 37704-15.
69. Hilton MJ, Tu X, Wu X, Bai S, Zhao H, Kobayashi T, et al. 2008. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med 14 (3): 306-14.
70. Fuentealba LC, Eivers E, Ikeda A, Hurtado C, Kuroda H, Pera EM, et al. 2007. Integrating patterning signals: Wnt/GSK3 regulates the duration of the BMP/Smad1 signal. Cell 131 (5): 980-93.
71. Sapkota G, Alarcon C, Spagnoli FM, Brivanlou AH, Massague J. 2007. Balancing BMP signaling through integrated inputs into the Smad1 linker. Mol Cell 25 (3): 441-54.
72. Nakayama K, Tamura Y, Suzawa M, Harada S, Fukumoto S, Kato M, et al. 2003. Receptor tyrosine kinases inhibit bone morphogenetic protein-Smad responsive promoter activity and differentiation of murine MC3T3-E1 osteoblast-like cells. J Bone Miner Res 18 (5): 827-35.
73. Hu MC, Rosenblum ND. 2005. Smad1, β-catenin and Tcf4 associate in a molecular complex with the Myc promoter in dysplastic renal tissue and cooperate to control Myc transcription. Development 132 (1): 215-25.
74. Labbe E, Letamendia A, Attisano L. 2000. Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-β and wnt pathways. Proc Natl Acad Sci U S A 97 (15): 8358-63.
75. Spinella-Jaegle S, Roman-Roman S, Faucheu C, Dunn FW, Kawai S, Gallea S, et al. 2001. Opposite effects of bone morphogenetic protein-2 and transforming growth factor-β 1 on osteoblast differentiation. Bone 29 (4): 323-30.
76. de Gorter DJJ, van Dinther M, Korchynskyi O, ten Dijke P. 2011. Biphasic effects of transforming growth factor β on bone morphogenetic protein-induced osteoblast differentiation. J Bone Miner Res 26 (6): 1178-87.
77. Matsaba T, Ramoshebi LN, Crooks J, Ripamonti U. 2001. Transforming growth factor-β 1 supports the rapid morphogenesis of heterotopic endochondral bone initiated by human osteogenic protein-1 via the synergistic upregulation of molecular markers. Growth Factors 19 (2): 73-86.
78. Zhao M, Qiao M, Harris SE, Chen D, Oyajobi BO, Mundy GR. 2006. The zinc finger transcription factor Gli2 mediates bone morphogenetic protein 2 expression in osteoblasts in response to hedgehog signaling. Mol Cell Biol 26 (16): 6197-208.
79. Li Y, Li A, Strait K, Zhang H, Nanes MS, Weitzmann MN. 2007. Endogenous TNF α lowers maximum peak bone mass and inhibits osteoblastic Smad activation through NF-κ B. J Bone Miner Res 22 (5): 646-55.
80. Mukai T, Otsuka F, Otani H, Yamashita M, Takasugi K, Inagaki K, et al. 2007. TNF-α inhibits BMP-induced osteoblast differentiation through activating SAPK/JNK signaling. Biochem Biophys Res Commun 356 (4): 1004-10.
81. Qiu T, Wu X, Zhang F, Clemens TL, Wan M, Cao X. 2010. TGF-β type II receptor phosphorylates PTH receptor to integrate bone remodelling signalling. Nat Cell Biol 12 (3): 224-34.